Skip to content

Pharma Invest Devos

Active
Private limited company (pre-2019)founded 2008active for 18 yearsAlsembergsesteenweg 91, 1501 Halle, BelgiumKBO/BCE: BE 0899.883.252

From the official registers: KBO 17 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

Pharma Invest Devos has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €618,231 and a net result of €61,887. Equity is growing by about 7.9% per year across the filed financial years. Its solvency ranks better than 84% of 22,679 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow ReportCompare
Pharma Invest DevosActiveChecked score 92/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 20-08-2008 Normal situation
Legal form
Private limited company (pre-2019)
Registered office
Alsembergsesteenweg 91, 1501 Halle
Activity
Retail sale of pharmaceutical products NACE 47730
Establishment unit
2.174.124.544 1501 Halle, since 01-10-2008
Financial year end
30 June
Peppol
Reachable since 07-12-2025
Company details

Who decides

Board
  • Devos LiesbetDirector
Holdings
Shares in 1 company Apotheek Devos
Board & ownership

How it is doing

92 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts to 30-06-2025
Gross margin
€100,642
▲ 62.9%
Turnover
≈ €320,000
estimated
Profit
€61,887
▲ 76.9%
Equity
€618,231
▲ 11.1%
Total assets
€821,619
▲ 10.6%
Staff
1 FTE
=
2025 accounts 26 days early
Filed on 05-01-2026PDF
Financials
Why 92raises riskLiquidity: current ratio 0.65, cash €10,957, halvedSector: Retail trade (NACE 47)lowers riskSize: total assets €821,619Founded in 2008Show the evidence

Checked score

Score 2025
92 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 59% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 100=
equity 75.2% of total assets
Liquidity 44-2
short-term debt 22.8% · cash 1.3%
Profitability 56+7
return on assets 7.5%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,270 companies, NACE 47, micro)
Last 24 months 11-2024: 0.1% 12-2024: 0.2%▲ +0.1 percentage points vs 11-2024 01-2025: 0.3%▲ +0.1 percentage points vs 12-2024highest value 02-2025: 0.1%▼ -0.2 percentage points vs 01-2025lowest value 03-2025: 0.1%● unchanged vs 02-2025lowest value 04-2025: 0.1%● unchanged vs 03-2025lowest value 05-2025: 0.1%● unchanged vs 04-2025lowest value 06-2025: 0.1%● unchanged vs 05-2025lowest value 07-2025: 0.1%● unchanged vs 06-2025lowest value 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.2%▲ +0.1 percentage points vs 12-2025 02-2026: 0.1%▼ -0.1 percentage points vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €55,000 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.65, compared with 0.25 in 2024, below 1; short-term debt: 22.8% and cash: 1.3% of total assets), and 24.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 92% on solvency, 42% on liquidity, 40% on profitability and 62% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Size: total assets €821,619
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Liquidity: current ratio 0.65, cash €10,957, halved
NBB · annual accounts
lowers risk · Founded in 2008
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 05-01-2026, 26 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
26 days early
2024
25 days early
2023
26 days early
2022
27 days early
2021
26 days early
2020
25 days early
2019
25 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 26 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 5 January (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-06-2026 year end01-11-2026 today31-01-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage

Key points

  • Positive: Among the best 5% on equitysector median €41,218 · 22,720 companies €618,231 View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
  • Positive: 7 profitable years in a rowprofit 2025: €61,887 7 years View

Documents

Annual accounts at the NBB

All 17 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about Pharma Invest Devos

What is the company number of Pharma Invest Devos?
0899.883.252. In Belgium the VAT number is the company number with BE in front: BE 0899.883.252.
Where is Pharma Invest Devos based?
The registered office is at Alsembergsesteenweg 91, 1501 Halle.Company details
What does Pharma Invest Devos do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of Pharma Invest Devos?
Private limited company (pre-2019) (BVBA).
When was Pharma Invest Devos founded?
On 20-08-2008.
Is Pharma Invest Devos still active?
Yes, Pharma Invest Devos is an active enterprise in the KBO register.
How many employees does Pharma Invest Devos have?
On average 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of Pharma Invest Devos?
≈ €320,000 in financial year 2025. Estimated from the gross margin of €100,642: probably between €220,000 and €620,000, based on 32 comparable companies, NACE 477.
Is Pharma Invest Devos profitable?
In financial year 2025, Pharma Invest Devos made a profit of €61,887.
Where can I find the annual accounts of Pharma Invest Devos?
Pharma Invest Devos filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
When are the next annual accounts of Pharma Invest Devos due?
By 31-01-2027, for financial year 2026.Timeline

Companies related to Pharma Invest Devos

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure